Needham Reiterates Buy on Biogen, Maintains $285 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Biogen (NASDAQ:BIIB) and maintains a $285 price target.
August 19, 2024 | 9:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Biogen and maintains a $285 price target.
The reiteration of a Buy rating and the maintenance of a $285 price target by a reputable analyst can positively influence investor sentiment and potentially drive short-term price appreciation for Biogen.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100